Please enable JavaScript.  This webapp requires JavaScript to work at its best.

AE monitoring & management guide

The guide supports healthcare professionals to manage adverse events (AE) that may result from the use of LENVIMA® (lenvatinib) in their differentiated thyroid cancer patients.

It provides guidance on how to monitor and manage most common AEs based on the Summary of Product Characteristics and recommendations made by a thyroid cancer steering committee.

Supporting documentation:

LENVIMA® 4 mg hard capsules Summary of Product Characteristics
LENVIMA® 10 mg hard capsules Summary of Product Characteristics

 

UK-LENA-23-00015  Date of preparation  January 2023